Table 1.
Patient Characteristics
| # Patients | 257 | |
|---|---|---|
| Age at SBRT, years | Median (Range) | 69 (47–89) |
| N = | 257 | |
| Clinical T-Stage | T1 | 176 (68.5) |
| T2 | 73 (28.4) | |
| T3 | 7 (2.7) | |
| T4 | 1 (0.4) | |
| NCCN Risk | Low | 43 (16.7) |
| Favorable-Intermediate | 84 (32.7) | |
| Unfavorable-Intermediate | 103 (40.1) | |
| High | 27 (10.5) | |
| Gleason Score | 6 | 50 (19.5) |
| 7 | 186 (72.4) | |
| 8 | 10 (3.9) | |
| 9 | 11 (4.3) | |
| RT Dose | 32.5 Gy | 24 (9.3) |
| 35.0 Gy | 28 (10.9) | |
| 37.5 Gy | 31 (12.1) | |
| 40.0 Gy | 174 (67.7) | |
| Pre-treatment PSA, ng/mL | Median (Range) | 6.4 (0.5–134.0) |
|
| ||
| Pre-treatment Prostate Volume | Median (Range) | 37.0 (9.0–121.0) |
| N = | 251 | |
| Extraprostatic capsule invasion | Negative-Possible | 192 (74.7) |
| Suspicious-Positive | 58 (22.6) | |
| Unknown | 7 (2.7) | |
| Use of ADT | Yes | 68 (26.5) |
| No | 189 (73.5) | |
|
| ||
| ADT Duration, months | Median (Range) | 4.6 (0.0–30.5) |
| N = | 67 | |
|
| ||
| IPSS Baseline Score | Median (Range) | 6.0 (0.0–24.0) |
| N = | 256 | |
|
| ||
| IIEF Baseline Score | Median (Range) | 9.0 (0.0–30.0) |
| N = | 250 | |
| Rectal Spacer Insertion | Yes | 90 (35) |
| No | 167 (65) | |